Gastroenterologist focusing on inflammatory bowel disease, with research interests including pharmacoepidemiology and risk-benefit analyses with biologics
Getting ready for #DDW2022 ? Planning which IBD sessions to attend? Below is the full IMIBD program to help you plan! Something interesting-all day, everyday. See you there!@ibddoctor
@CrohnsColitisFn's Team Challenge takes on the Day of the Tread in New Mexico in just 48 hours, and I'll be there to pedal 100 miles closer towards a cure. You can make a difference today by supporting the effort!
https://t.co/cdl3SktzAa
In this study using a novel combination of a retrospective cohort study & a simulation model, anti-TNF use in #Crohns was associated w/ improved QOL, measured as RTEs (remission-time equivalent), compared to continued corticosteroid use at 1 year: https://t.co/91MWDxMBe5
Where have we been and where should we be going with regards to pragmatic clinical research in IBD? Was an honor to be able to participate in and contribute to this important conversation: https://t.co/7Rh7isQFZr
Should we be screening our patients for EBV? Amneet Hans and @FrankIScottMD at the University of Colorado explore the potential ramifications based on recent epidemiologic data
'Editorial: which inflammatory bowel disease patients should be screened for Epstein‐Barr virus infection?' by Amneet K. Hans & Frank I. Scott
#IBD#EBV#gastroenterology
Read the whole Editorial FREE at https://t.co/cUZ11aQQtS
Our publication evaluating outcomes among patients with delayed IPAA vs IPAA at time of colectomy is now available. @bkocharmd@Hherf@UNCGastro | Oxford Academic https://t.co/zz27LT6pXZ
When considering a multi-step treatment algorithm for mod to severe UC, how should we be positioning Vedolizumab to maximize clinical benefits? https://t.co/9HeYXquROc